Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00652691 | Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | 48 | Mayo ClinicOTHER | 0 | Apr 8, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 |
| Mar 12, 2019 |
| clinicaltrials |
| NCT00003002 | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | completed | Phase 1 | 60 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03011320 | An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery | completed | Phase 1 | 3 | EndocyteINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT00002600 | Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT03551171 | The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | completed | Phase 1 | 42 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02582931 | MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT02418624 | Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer(REVIVAL) | completed | Phase 1 | 25 | The Netherlands Cancer InstituteOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer(BMS-247550) | completed | Phase 1 | 40 | Albert Einstein College of MedicineOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00410553 | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02146313 | A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | completed | Phase 1 | 35 | Genentech, Inc.INDUSTRY | 1 | Jun 21, 2018 | clinicaltrials |
| NCT00228319 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | completed | Phase 1 / Phase 2 | 27 | Jeanne Drisko, MD, CNS, FACNOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT02000778 | EC17 for Intraoperative Imaging in Occult Ovarian Cancer | completed | Phase 1 | 10 | University of PennsylvaniaOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | completed | Phase 1 | 22 | Cascadian Therapeutics Inc.INDUSTRY | 1 | May 17, 2018 | clinicaltrials |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT01219777 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | completed | Phase 1 | 9 | Ritu SalaniOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00474669 | A Phase I Study of Intraperitoneal Hyperthermic Docetaxel(IP) | completed | Phase 1 | 30 | University of LouisvilleOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00005023 | Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | completed | Phase 1 | — | University of WashingtonOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01256268 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | completed | Phase 1 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02482090 | TIL Therapy for Metastatic Ovarian Cancer | completed | Phase 1 | 6 | Inge Marie SvaneOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT02237690 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | completed | Phase 1 | 30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | completed | Phase 1 | 22 | Verastem, Inc.INDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT00626873 | Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary | completed | Phase 1 | 67 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01248949 | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | completed | Phase 1 | 162 | MedImmune LLCINDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01248273 | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer(PAZPET-1) | completed | Phase 1 | 16 | Imperial College LondonOTHER | 1 | Mar 10, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2019source: clinicaltrials